Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	66.06B
Revenue (ttm)	14.37B
Net Income (ttm)	1.51B
Shares Out	n/a
EPS (ttm)	0.86
PE Ratio	43.65
Forward PE	30.07
Dividend	0.22 (0.85%)
Ex-Dividend Date	Jul 4, 2025

Volume	10,755,950
Average Volume	13,861,997
Open	27.00
Previous Close	26.88
Day's Range	26.82 - 28.62
52-Week Range	10.46 - 29.48
Beta	0.92
RSI	60.95
Earnings Date	Oct 27, 2025

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotide...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 21,370
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial numbers in CNY